Active — Not RecruitingNot Applicable

Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant

United States72 participantsStarted 2018-11-13

Plain-language summary

This trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant. Identifying biomarkers (molecules that can indicate normal or abnormal processes) may help researchers develop a blood test that can be used to predict how well patients will process and respond to cyclophosphamide.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Scheduled to undergo allogeneic hematopoietic cell transplant (HCT) with a haploidentical donor. * Allogeneic HCT scheduled to treat any underlying disease. Patients with nonmalignant diseases or cancer are eligible * Scheduled to receive post-transplant cyclophosphamide (any dose, any number of doses, any dosing frequency) as part of their post-graft immunosuppression or GVHD prophylaxis. Patients enrolled on treatment protocols that include post transplant cyclophosphamide (PTCy) but do not include mycophenolate mofetil (MMF) or tacrolimus can participate * Willingness to: * Provide blood * Permit medical record review

What they're measuring

Mathematical models of cyclophosphamide (CY) and mycophenolic acid pharmacokinetics (PK) with t cell effects.

Timeframe: Up to day 21

Trial details

NCT IDNCT04160390

SponsorCity of Hope Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-04-24

View on ClinicalTrials.gov More Allogeneic Hematopoietic Stem Cell Transplant Recipient trials